FDA Oversight of Clinical Trials is “Grossly Inadequate” Say Experts
Maryanne Demasi On 25 September 2020, the US Food and Drug Administration (FDA) received a complaint by Brook Jackson who had been working for Ventavia Research Group, a Texas based company hired to run clinical trials for Pfizer’s covid-19 mRNA vaccine. Jackson, a regional director, had witnessed problems at three trial sites she was overseeing […]
Chemotherapy: The Scary, Staggering Truth About the Fraud
Vernon Coleman Over the years I have repeatedly found that all medical recommendations are best treated with a large dose of scepticism. Nowhere is this more true than in the treatment of cancer. … Chemotherapy might improve a patient’s chances of survival by three to five per cent though that modest figure is usually over […]
Combining COVID-19 BA4/5 and Influenza mRNA
Peter A. McCullough Recently, both Pfizer and Moderna announced they were developing a combination injection utilizing mRNA coding for the BA4/BA5 Omicron subvariant and new mRNA coding for antigens contained in the influenza virus. Because the COVID-19 component is under Emergency Use Authorization plus questionable unorthodox licensure meant to provide the legal basis for a […]
The Lethal Dangers of the Billion-dollar Vaccine Business with Government Approval … Safer Stuff is Available. Here’s Why You Haven’t Been Getting It
Andrea Rock When federal health officials and pediatricians refrain from warning the public about risks out of fear that parents will stop immunizing their children, they insult parents’ intelligence and endanger the public’s health. Parents deserve the facts so they can make informed choices. Geneticist and former NIH researcher Mark Geier says that when he […]
“Is Curing Patients a Sustainable Business Model?” Goldman Sachs Analysts Ask
Beth Mole One-shot cures for diseases are not great for business—more specifically, they’re bad for longterm profits—Goldman Sachs analysts noted in an April 10 report for biotech clients … The investment banks’ report, titled “The Genome Revolution,” asks clients the touchy question: “Is curing patients a sustainable business model?” The answer may be “no,” according […]
Acute Kidney Injury Associated with Remdesivir: A Comprehensive Pharmacovigilance Analysis of COVID-19 Reports in FAERS
Bin Wu et al. fphar-2022-692828 1..8 Acute kidney injury (AKI) is a common complication among patients with the novel coronavirus (COVID-19). COVID-19 along with AKI usually resulted in a poor prognosis for those affected. Remdesivir is a novel antiviral drug that was urgently approved for the treatment of COVID-19. In the current study, safety data […]
Potential Cardiotoxic Effects of Remdesivir on Cardiovascular System: A Literature Review
Maryam Nabati and Homa Parasee Corona disease 2019 (COVID-19) pandemic continues to spread around the world with no efficacious treatment. Intravenous remdesivir is the only authorized drug for treatment of COVID-19 disease under an Emergency Use Authorization. Remdesivir is a 1′-cyano-substituted adenosine nucleotide prodrug which inhibits viral RNA synthesis. This metabolite is an adenosine analog […]
Cardiovascular Drug Interactions with Nirmatrelvir/Ritonavir [Paxlovid] in Patients with COVID-19
Sonu Abraham et al. Nirmatrelvir-ritonavir (NMVr) is used to treat symptomatic, nonhospitalized patients with coronavirus disease-2019 (COVID-19) who are at high risk of progression to severe disease. Patients with cardiovascular risk factors and cardiovascular disease are at a high risk of developing adverse events from COVID-19 and as a result have a higher likelihood of […]
